These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

280 related articles for article (PubMed ID: 29338608)

  • 1. Immunotherapy of cancer: targeting cancer during active disease or during dormancy?
    Shah SA; Zarei M; Manjili SH; Guruli G; Wang XY; Manjili MH
    Immunotherapy; 2017 Sep; 9(11):943-949. PubMed ID: 29338608
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mechanisms and therapeutic potentials of cancer immunotherapy in combination with radiotherapy and/or chemotherapy.
    Yu WD; Sun G; Li J; Xu J; Wang X
    Cancer Lett; 2019 Jun; 452():66-70. PubMed ID: 30902563
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immunotherapy: enhancing the efficacy of this promising therapeutic in multiple cancers.
    Inthagard J; Edwards J; Roseweir AK
    Clin Sci (Lond); 2019 Jan; 133(2):181-193. PubMed ID: 30659159
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immunomodulation in cancer.
    Hegmans JP; Aerts JG
    Curr Opin Pharmacol; 2014 Aug; 17():17-21. PubMed ID: 25011112
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prospects in cancer immunotherapy: treating advanced stage disease or preventing tumor recurrence?
    Manjili MH; Payne KK
    Discov Med; 2015 Jun; 19(107):427-31. PubMed ID: 26175400
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Cancer Immunogram as a Framework for Personalized Immunotherapy in Urothelial Cancer.
    van Dijk N; Funt SA; Blank CU; Powles T; Rosenberg JE; van der Heijden MS
    Eur Urol; 2019 Mar; 75(3):435-444. PubMed ID: 30274701
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunotherapy in hepatocellular carcinoma.
    Buonaguro L; Mauriello A; Cavalluzzo B; Petrizzo A; Tagliamonte M
    Ann Hepatol; 2019; 18(2):291-297. PubMed ID: 31047849
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prevailing over T cell exhaustion: New developments in the immunotherapy of pancreatic cancer.
    Bauer C; Kühnemuth B; Duewell P; Ormanns S; Gress T; Schnurr M
    Cancer Lett; 2016 Oct; 381(1):259-68. PubMed ID: 26968250
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immunotherapy for colorectal cancer.
    Koido S; Ohkusa T; Homma S; Namiki Y; Takakura K; Saito K; Ito Z; Kobayashi H; Kajihara M; Uchiyama K; Arihiro S; Arakawa H; Okamoto M; Gong J; Tajiri H
    World J Gastroenterol; 2013 Dec; 19(46):8531-42. PubMed ID: 24379570
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The Combination of New Immunotherapy and Radiotherapy: A N ew Potential Treatment for Locally Advanced Non-Small Cell Lung Cancer.
    Sacco PC; Maione P; Guida C; Gridelli C
    Curr Clin Pharmacol; 2017; 12(1):4-10. PubMed ID: 27908252
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The immune contexture in cancer prognosis and treatment.
    Fridman WH; Zitvogel L; Sautès-Fridman C; Kroemer G
    Nat Rev Clin Oncol; 2017 Dec; 14(12):717-734. PubMed ID: 28741618
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Recent progress in therapeutic antibodies for cancer immunotherapy.
    Lee A; Sun S; Sandler A; Hoang T
    Curr Opin Chem Biol; 2018 Jun; 44():56-65. PubMed ID: 29885949
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Non-steroidal anti-inflammatory drugs, tumour immunity and immunotherapy.
    Hussain M; Javeed A; Ashraf M; Al-Zaubai N; Stewart A; Mukhtar MM
    Pharmacol Res; 2012 Jul; 66(1):7-18. PubMed ID: 22449788
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immunological Effects of Conventional Chemotherapy and Targeted Anticancer Agents.
    Galluzzi L; Buqué A; Kepp O; Zitvogel L; Kroemer G
    Cancer Cell; 2015 Dec; 28(6):690-714. PubMed ID: 26678337
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inhibiting the inhibitors: evaluating agents targeting cancer immunosuppression.
    Whiteside TL
    Expert Opin Biol Ther; 2010 Jul; 10(7):1019-35. PubMed ID: 20415597
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A Theoretical Basis for the Efficacy of Cancer Immunotherapy and Immunogenic Tumor Dormancy: The Adaptation Model of Immunity.
    Manjili MH
    Adv Cancer Res; 2018; 137():17-36. PubMed ID: 29405975
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Rationale for anti-CD137 cancer immunotherapy.
    Makkouk A; Chester C; Kohrt HE
    Eur J Cancer; 2016 Feb; 54():112-119. PubMed ID: 26751393
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Metronomic chemotherapy and immunotherapy in cancer treatment.
    Chen YL; Chang MC; Cheng WF
    Cancer Lett; 2017 Aug; 400():282-292. PubMed ID: 28189534
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Harnessing immune checkpoints in myeloid lineage cells for cancer immunotherapy.
    Park SY; Kim IS
    Cancer Lett; 2019 Jun; 452():51-58. PubMed ID: 30910590
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tumor infiltrating regulatory T cells: tractable targets for immunotherapy.
    Khan AR; Dovedi SJ; Wilkinson RW; Pritchard DI
    Int Rev Immunol; 2010 Oct; 29(5):461-84. PubMed ID: 20839911
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.